Pathos AI

Active#5 worldwide · AI drug discovery

AI drug discovery

HQUnited States

Last roundSeries D · May 2025

Uback rankings

Ranking	Tier	Rank	Edition	Next update
AI drug discovery · worldwide	Top 13	#5	Edition 0 (beta) · Sep 2026	21 Nov 2026

Rank historySep 2026 · #5 AI drug discoveryFirst edition: no movements yet.

Estimated valuation

AI · AI drug discovery ranking (worldwide)

≈ USD 1.8bnUSD 1.4–2.2bn · Unicorn High confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Anchor: Last known equity round: Series D · USD 365M · May 2025
Published valuation: USD 1.6bn · May 2025

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

Date	Round	Amount	Type	Investors	Source
May 2025	Series D	USD 365M	Equity	NEA, General Atlantic	finance.yahoo.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Pathos AI as a PDF, on one of three angles only:

ValuationWhat is Pathos AI worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

Pathos AI is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in ai drug discovery Name Pathos AI as a preferred company (measures demand, promises nothing)

AI drug discovery poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Pathos AI?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements3 sources

Read by the AI at the next edition.

Comparable companies in ai drug discovery

Full ai drug discovery ranking →

Enveda#4United StatesUnicorn Formation Bio#6United StatesUnicorn Xaira Therapeutics#3United StatesUnicorn Iambic Therapeutics#7United StatesUnicorn

Investors in Pathos AI: NEA · General Atlantic

Sources. finance.yahoo.com · siliconangle.com · fiercebiotech.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.